IFM Investors Pty Ltd purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) during the third quarter, according to its most recent filing with the SEC. The fund purchased 6,348 shares of the medical instruments supplier’s stock, valued at approximately $1,244,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Colony Group LLC grew its stake in shares of Becton, Dickinson and by 13.0% in the 1st quarter. Colony Group LLC now owns 11,650 shares of the medical instruments supplier’s stock worth $2,137,000 after buying an additional 1,342 shares in the last quarter. Bfsg LLC purchased a new position in shares of Becton, Dickinson and in the 1st quarter worth $1,954,000. Bragg Financial Advisors Inc grew its stake in shares of Becton, Dickinson and by 0.8% in the 1st quarter. Bragg Financial Advisors Inc now owns 44,682 shares of the medical instruments supplier’s stock worth $8,196,000 after buying an additional 375 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Becton, Dickinson and in the 1st quarter worth $101,993,000. Finally, Green Square Capital LLC purchased a new position in shares of Becton, Dickinson and in the 1st quarter worth $580,000. Institutional investors own 88.60% of the company’s stock.

A number of equities analysts have commented on the stock. Royal Bank of Canada reissued a “hold” rating and issued a $210.00 price objective on shares of Becton, Dickinson and in a research note on Wednesday, October 25th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target for the company in a research note on Tuesday, October 31st. Wells Fargo & Company initiated coverage on shares of Becton, Dickinson and in a research note on Friday, September 22nd. They set an “outperform” rating and a $225.00 price target for the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $245.00 price target on shares of Becton, Dickinson and in a research note on Friday, November 3rd. Finally, Morgan Stanley lifted their price target on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $217.08.

Becton, Dickinson and Company (NYSE:BDX) opened at $218.99 on Wednesday. Becton, Dickinson and Company has a 52 week low of $161.50 and a 52 week high of $229.68. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. The company has a market cap of $49,769.94, a PE ratio of 23.00, a P/E/G ratio of 1.71 and a beta of 1.07.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The firm’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.12 EPS. analysts predict that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.37%. This is a boost from Becton, Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date of this dividend is Thursday, December 7th. Becton, Dickinson and’s payout ratio is 64.52%.

ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.thecerbatgem.com/2017/12/13/ifm-investors-pty-ltd-purchases-new-holdings-in-becton-dickinson-and-company-bdx.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related stocks with our FREE daily email newsletter.